- Home
- MNPR
as 12-17-2024 4:00pm EST
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WILMETTE |
| Market Cap: | 113.5M | IPO Year: | 2019 |
| Target Price: | $27.33 | AVG Volume (30 days): | 93.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.54 - $38.50 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Monopar Therapeutics Inc. (MNPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Radhakrishnan Karthik | MNPR | Chief Financial Officer | Oct 28 '24 | Buy | $16.25 | 1,550 | $25,187.50 | 1,550 |
Latest Monopar Therapeutics Inc. News
MNPR Breaking Stock News: Dive into MNPR Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Monopar Therapeutics Shares Jump After First Patient Dosed in Cancer Therapy
GlobeNewswire
13 days ago
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
GlobeNewswire
15 days ago
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
GlobeNewswire
a month ago
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
MT Newswires
2 months ago
Monopar Therapeutics Closes $19.2 Million Common Stock Offering
GlobeNewswire
2 months ago
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
MT Newswires
2 months ago
Monopar Therapeutics Prices Best Efforts Public Offering at $16.25 per Share
GlobeNewswire
2 months ago
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
Compare MNPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNPR Monopar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.